11th International Symposium on Minimal Residual Cancer

May 3-5, 2018
Le Corum
MONTPELLIER, FRANCE

Organizers:
Catherine Alix-Panabières (Montpellier, France)
Klaus Pantel (Hamburg, Germany)

www.ismrc2018.com

Final Program
Dear Colleagues and Friends,

We warmly welcome you to the 11th International Symposium on Minimal Residual Cancer in Montpellier in the south of France. These international ISMRC meetings started in 1996 and have established themselves, every other year, as a premier event focusing on Minimal Residual Cancer in patients with solid tumors.

The MONTPELLIER ISMRC meeting is a great opportunity to gather during three days, researchers from academia and industry to share information about the most recent technical developments, clinical trials and late breaking news.

The 2018 meeting in Montpellier is organized together with the established EU-IMI consortium CANCER-ID and brings together basic and clinical researchers from academia and companies. The MONTPELLIER-ISMRC 2018 program will focus on LIQUID BIOPSY in a broader sense and will include presentations on Circulating Tumor Cells (CTCs) as well as circulating nucleic acids (DNA, miRNA) and exosomes, with emphasis on clinical studies as well as the biology of metastasis, including cancer stemness, dormancy, epithelial-mesenchymal transition and immunomodulation of tumor cells.

Besides invited plenary talks by leading international experts, the MONTPELLIER-ISMRC 2018 includes oral communications and poster presentations selected from the submitted abstracts to support young investigators as well as a session for companies developing new technologies for liquid biopsy. We invite you to submit your abstract for consideration by our Advisory Committee for presentation at the MONTPELLIER-ISMRC 2018 meeting.

After great cities like Munich, Berlin, Oslo, San Francisco, Hamburg, Athens, Osaka & Paris, the next ISMRC will take place May 3-5, 2018 at the Corum in Montpellier, France. We hope that you will enjoy your time attending this 11th ISMRC meeting in MONTPELLIER and enjoy the opportunity to exchange information and establish long lasting collaborations with your colleagues.

We will be very happy to welcome you in May 2018 in Montpellier!
Scientific Committee

Catherine Alix-Panabières (Montpellier, France)
Klaus Pantel (Hamburg, Germany)
Evi Lianidou (Athens, Greece)
Jean-Yves Pierga (Paris, France)
Nick Stoecklein (Düsseldorf, Germany)
Michael Speicher (Graz, Austria)

Confirmed Speakers

Catherine Alix-Panabières (Montpellier, France)
Emmanuel Antonarakis (Baltimore, USA)
Carlos Caldas (Cambridge, UK)
George Calin (Houston, USA)
Lewis Chodosh (Philadelphia, USA)
Michael Clarke (Stanford, USA)
Luis Diaz (Baltimore, USA)
Caroline Dive (Manchester, UK)
Hugh Fan (Gainsville, USA)
Françoise Farace (Paris, France)
Thomas Friedl (Ulm, Germany)
Jérôme Galon (Paris, France)
Renaud Garrel (Montpellier, France)
Paola Gazzaniga (Roma, Italy)
Christine Gilles (Liège, Belgium)
Daniel Hayes (Michigan, USA)
Paul Hofman (Nice, France)
Dave Hoon (Santa Monica, USA)
Stefanie Jeffrey (Stanford, USA)
Raghu Kalluri (Houston, USA)
Yibin Kang (Princeton, USA)
Evi Lianidou (Athens, Greece)
Dennis Lo (Hong-Kong, China)
David Lyden (New-York, USA)
Dario Marchetti (Houston, USA)
Joan Massagué (New-York, USA)
Thibaut Mazaré (Montpellier, France)
Klaus Pantel (Hamburg, Germany)
Jean-Yves Pierga (Paris, France)
Alain Puisieux (Lyon, France)
Howard Scher (New-York, USA)
Jonathan Sleeman (Heidelberg, Germany)
Michael Speicher (Graz, Austria)
Nick Stoecklein (Düsseldorf, Germany)
Leon Terstappen (Twente, The Netherlands)
Frédéric Thomas (Montpellier, France)
Jean-Paul Thiery (Paris, France)
Rik Thompson (Brisbane, Australia)
Robert Weinberg (Boston, USA)
Tom Würdinger (Amsterdam, The Netherlands)
Bruce Zetter (Boston, USA)

Endorsement

Visit us at thermofisher.com/liquidbiopsy

For Research Use Only. Not for use in diagnostic procedures.
© 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.
## Program Summary

### Thursday
#### May 3rd, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8h20</td>
<td>Welcome Remarks</td>
</tr>
<tr>
<td>8h30</td>
<td>Opening</td>
</tr>
<tr>
<td>9h00</td>
<td>Keynote Lecture: Liquid Biopsy: Biology and Clinical Applications</td>
</tr>
<tr>
<td>9h30</td>
<td>Session 1 (I/II): Cancer Cell Stemness and Epithelial-Mesenchymal Plasticity</td>
</tr>
<tr>
<td>10h50-11h20</td>
<td>Coffee Break &amp; Visit of the Exhibition</td>
</tr>
<tr>
<td>11h20</td>
<td>Session 1 (II/II): Cancer Cell Stemness and Epithelial-Mesenchymal Plasticity</td>
</tr>
<tr>
<td>12h35-13h45</td>
<td>Lunch Break &amp; Visit of the Exhibition</td>
</tr>
<tr>
<td>13h45</td>
<td>Session 2: Evolution &amp; Cancer</td>
</tr>
<tr>
<td>14h10</td>
<td>Session 3 (I/II): Immune System and Cancer</td>
</tr>
<tr>
<td>14h35</td>
<td>Session 4: Poster Sessions 14h35 Poster Session 1 15h20 Poster Session 2</td>
</tr>
<tr>
<td>16h05-16h35</td>
<td>Coffee Break &amp; Visit of the Exhibition</td>
</tr>
<tr>
<td>16h35</td>
<td>Session 5: Selected Oral Presentations</td>
</tr>
<tr>
<td>20h00</td>
<td>Gala Dinner</td>
</tr>
</tbody>
</table>

### Friday
#### May 4th, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8h30</td>
<td>Session 6 (I/II): Biology of Tumor Cell Dissemination and Metastasis</td>
</tr>
<tr>
<td>9h30</td>
<td>Exhibition</td>
</tr>
<tr>
<td>9h50-10h20</td>
<td>Coffee Break &amp; Visit of the Exhibition</td>
</tr>
<tr>
<td>10h20</td>
<td>Session 6 (II/II): Biology of Tumor Cell Dissemination and Metastasis</td>
</tr>
<tr>
<td>11h10</td>
<td>Session 7 (I/II): Circulating Tumor Cells</td>
</tr>
<tr>
<td>12h25-13h35</td>
<td>Lunch Break &amp; Visit of the Exhibition</td>
</tr>
<tr>
<td>13h35</td>
<td>Session 7 (II/II): Circulating Tumor Cells</td>
</tr>
<tr>
<td>15h15-15h45</td>
<td>Coffee Break &amp; Visit of the Exhibition</td>
</tr>
<tr>
<td>15h45</td>
<td>Session 8: Circulating Cell-Free Tumor DNA and Exosomes</td>
</tr>
<tr>
<td>16h10</td>
<td>Session 10: Emerging Commercial Technologies</td>
</tr>
<tr>
<td>17h00</td>
<td>Closing Remarks with Poster and Travel Awards</td>
</tr>
</tbody>
</table>

### Saturday
#### May 5th, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8h30</td>
<td>Session 9 (I/II): CTCs as liquid biopsy in Clinical Studies</td>
</tr>
<tr>
<td>9h05</td>
<td>Exhibition</td>
</tr>
<tr>
<td>10h35-11h05</td>
<td>Coffee Break &amp; Visit of the Exhibition</td>
</tr>
<tr>
<td>11h05</td>
<td>Session 9 (II/II): CTCs as liquid biopsy in Clinical Studies</td>
</tr>
<tr>
<td>13h15-14h25</td>
<td>Lunch Break &amp; Visit of the Exhibition</td>
</tr>
<tr>
<td>14h25</td>
<td>Session 10: Emerging Commercial Technologies</td>
</tr>
<tr>
<td>15h15</td>
<td>Session 3 (II/II): Immune System and Cancer</td>
</tr>
<tr>
<td>15h40-16h10</td>
<td>Coffee Break &amp; Visit of the Exhibition</td>
</tr>
<tr>
<td>16h10</td>
<td>Session 11: Circulating Cell-Free miRNA and Platelets</td>
</tr>
<tr>
<td>17h00</td>
<td>Closing Remarks with Poster and Travel Awards</td>
</tr>
</tbody>
</table>
**Thursday May 3, 2018**

---

**08h20** Welcome Remarks  
*Catherine Alix-Panabières (France), Pantel K. (Germany)*

**08h30** Opening  
Director ITMO & INCa (National Institute of Cancer Research) - *Christine Chomienne*  
General Director, CHU Hospital Montpellier - *Thomas Le Ludec*  
Dean, Faculty of Medicine, CHU Hospital Montpellier - *Michel Mondain*  
President of the University of Montpellier - *Philippe Soureil*  
Mayor of Montpellier - *Philippe Saurel*  
Regional President - *Carole Delga*

**09h00** Keynote Lecture: Liquid Biopsy: Biology and Clinical Applications  
*Klaus Pantel (Germany)*

---

### SESSION 1  
**Cancer cell stemness and epithelial-mesenchymal plasticity**  
*Chairmen: Mani Sendurai (USA), Jean-Paul Thiery (France)*

**09h30** Keynote Lecture: Role of Epithelial-Mesenchymal Transition in Tumor Progression  
*Robert Weinberg (USA)*

**10h00** Epithelial mesenchymal transition in carcinoma; therapeutic intervention  
*Jean-Paul Thiery (France)*

**10h25** Epithelial-mesenchymal plasticity in breast cancer model systems; Implications for metastatic progression of clinical breast cancer.  
*Rik Thompson (Australia)*

---

**10h50-11h20 // Coffee Break & Visit of the Exhibition**

**11h20** Identification of markers for metastatic, drug resistant breast cancer stem cells  
*Michael Clarke (USA)*

---

**11h45** EMT-driven coagulation: impact for Circulating Tumor Cells  
*Christine Gilles (Belgium)*

**12h10** ZEB1, an EMT inducer at the crux of stemness, cancer genetics and metastatic dissemination  
*Alain Puisieux (France)*

**12h35-13h45 // Lunch Break & Visit of the Exhibition**

---

### SESSION 2  
**Evolution & cancer**  
*Chairman: Jean-Marc Lacorte (France)*

**13h45** An evolutionary perspective of cancer  
*Frédéric Thomas (France)*

---

### SESSION 3  
**Immune system and cancer (I/II)**  
*Chairman: Jean-Marc Lacorte (France)*

**14h10** Monitoring immunotherapies with liquid biopsies  
*Paola Gazzaniga (Italy)*

---

### SESSION 4  
**Poster sessions**

**14h35** Poster Session 1 (in the Exhibition area)

**15h20** Poster Session 2 (in the Exhibition area)

---

**16h05-16h35 // Coffee Break & Visit of the Exhibition**
Thursday May 3, 2018

Final Program & Sessions

SESSION 5
Oral communications
Chairpersons: Evi Lianidou (Greece), Nick Stoecklein (Germany)

16h35 Disseminated tumor cells (DTC) of high-risk neuroblastoma patients undergo transcriptional alterations during disease progression – RNA-seq and first steps towards DTC-derived zebrafish xenografts
Rifatbegovic F. (Austria), Taschner-Mandl S. (Austria), Pascoal S. (Austria), Distel M. (Austria), Abbasi R. (Austria), Frech C. (Austria), Ziegler A. (Austria), Westermann F. (Germany), Ambros I.M. (Austria), Ambros P.F. (Austria)

16h50 PD-L1-expressing circulating breast cancer cells: Correlation with tissue expression and clinical evolution
Jacot W. (France), Mazel M. (France), Mollevi C. (France), Pauderoux S. (France), D’Hondt V. (France), Cayrefourcq L. (France), Duteil A. (France), Viau M. (France), Maudelonde T. (France), Guiu S. (France), Alix Panabieres C. (France)

17h05 RANK expression in Circulating Tumor Cells (CTCs): clinical utility in monitoring metastatic Breast cancer patients (MBC) under Denosumab treatment
Zamarchi R. (Italy), Facchinetti A. (Italy), Rossi E. (Italy), Zoccoli A. (Italy), Iuliani M. (Italy), Pantano F. (Italy), Bruno V. (Italy), Tonini G. (Italy), Santini D. (Italy)

17h20 Microsatellite instability detection in circulating blood DNA by droplet-digital PCR
Silveira A. (France), Bidard F.C. (France), Bieche I. (France), Melaabi S. (France), Cabel L. (France), Buecher B. (France), Pierga J.Y. (France), Stern M.H. (France), Proudhon C. (France)

17h35 The novel detection of the EGFR-T790M mutation in exhaled breath condensate
Smyth R. (Ireland), Toomey S. (Ireland), Sartori A. (Germany), O’Hanrahan E. (Ireland), Cuffe S. (Ireland), Breathnach O. (Ireland), Morgan R. (Ireland), Hennessy B. (Ireland)

17h50 Visualisation and quantification of AR-V7, AR-FL, PSA and KRAS point mutations in CTCs
El-Heliebi A. (Austria), Hille C. (Germany), Laxman N. (Sweden), Svedlund J. (Sweden), Haudum C. (Austria), Erkan E. (Austria), Kroneis T. (Austria), Chen S. (Austria), Smolle M. (Austria), Rossmann C. (Austria), Krzywkowski T. (Sweden), Ahlford A. (Sweden), Darai E. (Sweden), von Amsberg G. (Germany), Winfried A. (Germany), König F. (Germany), Lühr M. (Sweden), de Kruijff I. (The Netherlands), Riethdorf S. (Germany), M. Gorges T. (Germany), Pantel K. (Germany), Bauernhofer T. (Österreich), Nilsson M. (Sweden), Sedlmayr P. (Austria)

18h05 Change in circulating microRNA expression during neoadjuvant chemoradiation for rectal cancer
Spring K. (Australia)
Friday May 4, 2018

— SESSION 6
Biology of tumor cell dissemination and metastasis
Chairmen: David Azria (France), Bruce Zetter (USA)

08h30  Keynote Lecture: Latency, Immune Evasion, and Outbreak of Metastatic Stem Cells
Joan Massagué (USA)

09h00  Stromal niches for bone metastasis
Yibin Kang (USA)

09h25  Targeting Aggressive Cancers
Bruce Zetter (USA)

09h50-10h20 // Coffee Break & Visit of the Exhibition

10h20  Targeting tumor dormancy to prevent breast cancer recurrence
Lewis Chodosh (USA)

10h45  A new role for VEGF-C in metastatic conditioning of the lung
Jonathan Sleeman (Germany)

— SESSION 7
Circulating tumor cells (II/II)
Chairpersons: Paola Gazzağniga (Italy), Dan Hayes (USA)

13h35  Advancing CTC-based liquid biopsies
Nick Stoecklein (Germany)

14h00  CTC Isolation Methods and Clinical Treatment Monitoring
Hugh Fan (USA)

14h25  Circulating Tumor Cells, what have we learned
Leon Terstappen (The Netherlands)

14h50  Patient-derived models: opportunities, challenges, and newer tools for exploring the biology of metastasis
Stefanie Jeffrey (USA)

15h15-15h45 // Coffee Break & Visit of the Exhibition

— SESSION 8
Circulating cell-free tumor DNA and exosomes
Chairmen: Klaus Pantel (Germany), Michael Speicher (Austria)

15h45  Keynote Lecture: Towards Cancer Screening Using Circulating DNA
Dennis Lo (Hong Kong)

16h15  Cell-free DNA for minimal residual disease analysis
Luis Diaz (USA)

16h40  The impact of circulating tumor DNA analyses on precision oncology
Michael Speicher (Austria)

17h05  ctDNA in breast cancer
Carlos Caldas (UK)

17h30  Utility of new cfna approaches for assessment of cancer progression
Dave Hoon (USA)

17h55  Nanosized particles promote systemic effects of cancer
David Lyden (USA)

18h20  Developing Exosomes Based Platform for Diagnosis and Treatment of Cancer
Raghu Kalluri (USA)

20h00  GALA DINNER

12h25-13h35 // Lunch Break & Visit of the Exhibition
Saturday May 5, 2018

Final Program & Sessions

SESSION 10
Emerging commercial technologies
Chairmen: Leon Terstappen (The Netherlands), Hugh Fan (USA)

14h25 A robust method to study cancer heterogeneity in liquid biopsy
Nicolo Manaresi, PhD, Chief Scientific Officer MENARINI SILICON BIOSYSTEMS

14h45 Advancing Liquid Biopsy with Next Generation Sequencing
Kelli Bramlett, Director, R&D Clinical Next Generation Sequencing Division Life Sciences Solution, THERMO FISHER SCIENTIFIC

15h00 Sensitivity matters – Comparison of different methods for Liquid Biopsy testing
Pierre-Jean Lamy, Dr., AGENA BIOSCIENCE

SESSION 3
Immune system and cancer (II/II)
Chairman: Paul Hofman

15h15 The immune contexture of tumors: a novel view on cancer evolution
Jerome Galon (France)

15h40-16h10 Coffee Break & Visit of the Exhibition

SESSION 11
Circulating cell-free miRNA and platelets
Chairpersons: Tom Wurdinger (The Netherlands), Catherine Alix-Panabières (France)

16h10 Tumor-educated platelets for the detection of cancer
Tom Wurdinger (The Netherlands)

16h35 About Chomsky, patterns and cell to cell communication by non-coding RNAs
George Calin (USA)

17h00 Closing Remarks with Poster Awards supported by MDPI and Travel Awards supported by JANSSEN
14h35 - 15h20
Session 4: Poster Sessions 1 (in the Exhibition area)

**BIOLOGY OF TUMOR CELL DISSEMINATION AND METASTASIS**

**P-1**
Genomic analysis of bone marrow-derived disseminated neuroblastoma cells to identify relapse-seeding clone
Abbasi R. (Austria), Rifatbegovic F. (Austria), Brunner C. (Austria), Mann G. (Austria), Ziegler A. (Austria), Pötschger U. (Austria), Crazzolara R. (Austria), Usowicz M. (Poland), Benesch M. (Austria), Ebetsberger-Dachs G. (Austria), Chan G.C. (Hong Kong), Jones N. (Austria), Ladenstein R. (Austria), Ambros I.M. (Austria), Ambros P.F. (Austria)

**P-2**
Up-regulation of flotillins, new marker of metastatic development, induces an epithelial to mesenchymal transition
Genest M. (France), Plancharon D. (France), Comunale F. (France), Seveno M. (France), Gauthier-Rouvière C. (France), Bodin S. (France)

**P-3**
Droplet Microfluidic Platform for Single-Cell RT-qPCR Analysis
Hajji I. (France), Serra M. (France), Geremie L. (France), Renault R. (France), Viwy J.L. (France), Descroix S. (France), Ferraro D. (France)

**P-4**
Prognostic value of disseminated tumor cells in patients with luminal breast cancer

**P-5**
HER2 activation by FHIT downregulation in lung tumor cells
Da Silva J. (France), Jouaida A. (France), Bonnomet A. (France), Birrembaut P. (France), Dalstein V. (France), Polette M. (France), Nawrocki-Raby B. (France)

**P-6**
Testing a label-free CTC-enrichment method to isolate viable pancreatic cancer CTC
Guglielmi R. (Germany), Neves R.P.L. (Germany), Raba K. (Germany), Stoceklein N.H. (Germany)

**CIRCULATING CELL-FREE TUMOR DNA**

**P-12**
CircSarc; A non-invasive insight into the sarcoma genome

**P-13**
HPV circulating tumor DNA to monitor the efficacy of chemoradiotherapy in non-metastatic anal carcinoma
Bernard A. (France), Cabel L. (France), Jeannot E. (France), Bieche I. (France), Vacher S. (France), Collens C. (France), Morel A. (France), Lièvre A. (France), Ozt J. (France), Minsa M. (France), Pierga J.Y. (France), Buechel B. (France), Mariani P. (France), Bidard F.C. (France), Cacheux W. (France)

**POSTER SESSIONS**

**P-8**
Characterization of Diffuse Low Grade Gliomas in vitro
Augustus M. (France), Leventoux N. (France), Rigou V. (France), Duffau H. (France), Hugnot J.P. (France)

**P-9**
European Liquid Biopsies Academy (ELBA) - Towards widespread clinical application of blood-based diagnostic tools
Koppers-Lalic D. (Netherlands), Wurdinger T. (Netherlands), Pantel K. (Germany), Rosell R. (Spain), Lyden D. (USA), Alix Panabieres C. (France), Baev V. (Bulgaria), Hockenberg M. (Spain), Fernandez Hilario A. (Spain), Karachaliou N. (Spain), Zaravni N. (Italy)

**P-10**
The importance of circulating tumor cells and circulating sphere forming cells in the course of disease in patients with malignant solid tumors
Lux D. (Germany)

**P-11**
Identification and monitoring of a high-level MET amplification in CTCs and cfDNA in an ALK-rearranged NSCLC patient treated with crizotinib, alectinib and ceritinib
Berger L.A. (Germany), Velthaus J.L. (Germany), Janning M. (Germany), Simon R. (Germany), Cao R. (USA), Bramlett K. (USA), Busan G. (Italy), Petini E. (Italy), Forcato C. (Italy), Tiemann M. (Germany), Pantel K. (Germany), Loges S. (Germany)

**P-118**
Locally Ablative Radiation Therapy of Human Small Cell Lung Cancer Decreases the Number of Spontaneous Metastases in Xenograft Models
Frenzel T. (Germany), Siekmann J. (Germany), Grohmann C. (Germany), Valentiner U. (Germany), Schmitz R. (Germany), Rieck K. (Germany), Feik H. (Germany), Schumacher U. (Germany), Krüll A. (Germany), Lange T. (Germany)

**P-12**
Characterization of Diffuse Low Grade Gliomas in vitro
Augustus M. (France), Leventoux N. (France), Rigou V. (France), Duffau H. (France), Hugnot J.P. (France)

**P-9**
European Liquid Biopsies Academy (ELBA) - Towards widespread clinical application of blood-based diagnostic tools
Koppers-Lalic D. (Netherlands), Wurdinger T. (Netherlands), Pantel K. (Germany), Rosell R. (Spain), Lyden D. (USA), Alix Panabieres C. (France), Baev V. (Bulgaria), Hockenberg M. (Spain), Fernandez Hilario A. (Spain), Karachaliou N. (Spain), Zaravni N. (Italy)

**P-10**
The importance of circulating tumor cells and circulating sphere forming cells in the course of disease in patients with malignant solid tumors
Lux D. (Germany)

**P-11**
Identification and monitoring of a high-level MET amplification in CTCs and cfDNA in an ALK-rearranged NSCLC patient treated with crizotinib, alectinib and ceritinib
Berger L.A. (Germany), Velthaus J.L. (Germany), Janning M. (Germany), Simon R. (Germany), Cao R. (USA), Bramlett K. (USA), Busan G. (Italy), Petini E. (Italy), Forcato C. (Italy), Tiemann M. (Germany), Pantel K. (Germany), Loges S. (Germany)

**P-118**
Locally Ablative Radiation Therapy of Human Small Cell Lung Cancer Decreases the Number of Spontaneous Metastases in Xenograft Models
Frenzel T. (Germany), Siekmann J. (Germany), Grohmann C. (Germany), Valentiner U. (Germany), Schmitz R. (Germany), Rieck K. (Germany), Feik H. (Germany), Schumacher U. (Germany), Krüll A. (Germany), Lange T. (Germany)
P-14
Evaluation of a new multiplex assay using droplet digital PCR for tracking sensitive and resistant mutations in ctDNA: comparison with Cobas and NGS
Denis J. A. (France), Guillerm E. (France), Henoff D. (France), Gobert A. (France), Lamy P. J. (France), Lacorte J. M. (France), Coulet F. (France), Fina F. (France)

P-15
Role of frequent chr13 q12.2 amplification in colorectal cancer patients
Zhou Q. (Österreich), Perakis S. (Austria), Ulz P. (Österreich), Pichler M. (Österreich), Gerger A. (Österreich), Bauerhofer T. (Österreich), Geigi J. B. (Austria), Heitzer E. (Austria), Speicher M. R. (Österreich)

P-16
Non-invasive genotyping of locally advanced rectal cancer patients using circulating tumour DNA
Toomey S. (Ireland), Sartori A. (Germany), Irwin D. (Australia), Carr A. (Ireland), Armstrong P. (Ireland), Farrelly A. (Ireland), O’Sullivan L. (Ireland), Bradshaw S. (Ireland), Smyth R. (Ireland), Workman J. (Ireland), Lee C. L. (Ireland), O’Neill B. (Ireland), Hennessy B. (Ireland)

P-17
Single-stranded library preparation does not preferentially enrich circulating tumor DNA
Moser T. (Austria), Ulz P. (Austria), Zhou Q. (Austria), Perakis S. (Austria), Geigi J. B. (Austria), Speicher M. R. (Austria), Heitzer E. (Austria)

P-18
Comparison study of manual and automated extraction systems for cell-free circulating DNA
Ockhardt A. (Deutschland), Shaw J. (Vereinigtes Königreich), Cowley C. (Vereinigtes Königreich), Joos H. (Germany)

P-19
Automation of Real-Time Quantitative PCR based Minimal Residual Disease Monitoring by Centrifugal Microfluidics
Juegl P. (Germany), Kipf E. (Deutschland), Eckert C. (Deutschland), Paust N. (Deutschland), Zengerle R. (Deutschland), Hutzenlaub T. (Deutschland)

P-20
Pre-analytical aspects of extracted circulating cell-free DNA: impact of storage conditions and exposure to freeze-thawing.
Qvick A. (Sweden), Hellenius G. (Sweden)

P-21
Concordance of genomic mutations in tissue vs circulating tumour DNA (ctDNA) in metastatic melanoma
Calapre L. (Australia), Giardina T. (Australia), Robinson C. (Australia), Reid A. (Australia), Al-Ogeili Z. (Australia), Pereira M. (Australia), Mcavoy A. (Australia), Warburton L. (Australia), Khattak M. A. (Australia), Meniawy T. (Australia), Millward M. (Australia), Amanuel B. (Australia), Ziman M. (Australia), Gray E. (Australia)

P-22
Circulating tumor DNA to personalize treatment in patients with RAS mutant metastatic colorectal cancer
Paola G. (Italy), Loreni F. (Italy), Raimondi C. (Italy), Chiara N. (Italy), Angela G. (Italy), Federica U. (Italy), Enrico C. (Italy)

P-23
DNA methylation analysis in liquid biopsy: a detailed study on quality control, sample storage and whole genome amplification procedures for downstream applications.
Mastoraki S. (Greece), Chimonidou M. (Greece), Tsanikou E. (Greece), Lianidou E. (Greece)

P-24
Activating ESR1 mutations detection by single ddPCR assay
Proudhon C. (France), Jeannot E. (France), Bidard F. C. (France), Cabib L. (France), Epaillard N. (France), El Ayachi R. (France), Noret A. (France), Vincent-Salomon A. (France), Pierga J. Y. (France), Bieche I. (France), Stern M. H. (France)

P-25
Development of a fully automated microfluidic magnetic fluidized bed for circulating tumor DNA detection
Alexandre L. (France), Proudhon C. (France), Bidard F. C. (France)

P-26
Patient-Specific Circulating Tumor DNA Detection during Palbociclib/Fulvestrant therapy in HR+/HER2- Metastatic Breast Cancer.
Darrigues L. (France), Proudhon C. (France), Bidard F. C. (France)

P-27
Mutation analysis in liquid biopsies and tissue segments of lung adenocarcinoma patients
Dietz S. (Germany), Riediger A. L. (Germany), Harms A. (Germany), Stenzinger A. (Germany), Worth A. (Germany), Schneider M. (Germany), Meister M. (Germany), Muley T. (Germany), Thomas M. (Germany), Sültmann H. (Germany)

P-28
TruePrime Liquid Biopsy: the first tool to amplify cell-free DNA
Picher À. (Spain), Juárez R. (Spain), Budeus B. (Germany)

P-29
Application of the Highly Sensitive SiMSen-Seq Assay and Seraseq Designed Reference Materials to Minimal Residual Disease Detection
Garlick K. (United States), Königshofer Y. (United States), Butler M. (United States), Egyud M. (United States), Stahlberg A. (Sweden), Godfrey T. (United States)

P-30
LIQBIOPSENS: A Novel, Reliable and Affordable Platform for Colorectal Cancer Patients Screening (H2020-IA 687785)
Garrido Navas M. D. C. (Spain), Robles Remacho A. (Spain), Delgado Urêna M. (España), Gonzalez Flores E. (España), Lopez Castro R. (España), Ilyne H. (Reino Unido), Díaz Mochon J. (España), Serrano M. J. (España)
POSTER SESSIONS

Thursday May 3, 2018

P-33
Circulating cell free tumor DNA: dynamics in patients with advanced and localized cancer disease
Hilke F.J. (Germany), Zwirner K. (Deutschland), Bitzer M. (Deutschland), Malek N. (Deutschland), Koott B. (Deutschland), Stephan O. (Deutschland), Gani C. (Deutschland), Riess O. (Deutschland), Zips D. (Deutschland), Welz S. (Deutschland), Christopher S. (Deutschland)

P-34
Analysis of cell free tumor DNA for the treatment monitoring in two patients with advanced melanoma
Hilke F.J. (Germany), Muller A. (Deutschland), Hahn M. (Deutschland), Klump B. (Deutschland), Sanja H. (Deutschland), Eigentler T. (Deutschland), Sinnberg T. (Deutschland), Niessner H. (Deutschland), Riess O. (Deutschland), Garbe C. (Deutschland), Roken M. (Deutschland), Forschner A. (Deutschland), Schroeder C. (Deutschland)

P-35
ThermoFisher NGS Assay for Low Frequency 0.01% Analyte Detection
Bramlett K. (Usa), Cao R. (Usa), Hanif K. (United States)

P-36
Verification of a complete Sample to Insight® liquid biopsy workflow - NGS of ccfDNA from stabilized blood
Ullius A. (Germany), Krenz T. (Germany), Sprenger-Haussels M. (Germany), Hubel R. (Germany), Voss T. (Germany), Provencher E. (United States), Buirkle T. (United States), Groezel D. (Germany)

P-37
Detection of tumor-associated gene mutations in cell-free DNA of early-stage non-small cell lung cancer patients
Kimura H. (Japan), Koba H. (Japan), Kasahara K. (Japan)

P-38
Evaluation of complete and quantitative size distribution of cfDNA as a monitoring marker in oncology.
Taly V. (France), Wang-Renault S. (France), Garrigou S. (France), Bouloungen-Rodat A. (France), Carrillon M.J. (France), Pacelli J. (France), Pietraz D. (France), Didevot A. (France), Bats A.S. (France), Bachet J.B. (France), Blons H. (France), Zaanan A. (France), Ginot F. (France), Laurent Puig P. (France)

P-39
Cell free DNA in radiation oncology: a beneficial biomarker to distinguish toxicity from infection?
Zwirner K. (Germany), Hilke F.J. (Germany), Demidov G. (Deutschland), Ossowski S. (Deutschland), Gani C. (Deutschland), Rieß O. (Deutschland), Zips D. (Deutschland), Welz S. (Deutschland), Schroeder C. (Deutschland)

P-119
Clinical implication of ctDNA analysis in advanced lung carcinoma patients using two different technologies: real-time PCR and MALDI-TOF
Lamy P.J. (France), Zornbach K. (Germany)

CIRCULATING TUMOR CELLS

P-40
Deep Learning to identify Circulating Tumor Cells by ACCEPT
Zeune L. (Netherlands), Van Dalum G. (Germany), Nanou A. (Netherlands), de Wit S. (Netherlands), Andree K. (Netherlands), Swennenhaus J. (Netherlands), Terstappen L. (Netherlands), Brune C. (Netherlands)

P-41
Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - results from the adjuvant SUCCESS A trial
Marie T. (Germany), Rack B. (Germany), Schneeweiss A. (Germany), Mueller V. (Germany), Fehm T. (Germany), Gade J. (Germany), Lorenz R. (Germany), Rezai M. (Germany), Tesch H. (Germany), Polasik A. (Germany), Schochter F. (Germany), de Gregorio A. (Germany), Ernst K. (Germany), Bekes I. (Germany), Mahner S. (Germany), Schindlbck C. (Germany), Beckmann M.W. (Germany), Fasching P.A. (Germany), Jani W. (Germany), Friedl T.W.P. (Germany)

P-42
The tumor-initiating capacity of prostate circulating tumor cells examined through a unique CTC-derived eXplant (CDX) model
Faugeroux V. (France), Pailler E. (France), Deas O. (France), Brulle-Soumare L. (France), Marty V. (France), Alexandrova K. (France), Andree K. (Netherlands), Schochter F. (Germany), de Gregorio A. (Germany), Ernst K. (Germany), Bekes I. (Germany), Mahner S. (Germany), Schindlbck C. (Germany), Beckmann M.W. (Germany), Fasching P.A. (Germany), Jani W. (Germany), Friedl T.W.P. (Germany)

P-43
Autologous cell lines established from circulating colon cancer cells captured at sequential liquid biopsies: a tool to investigate therapy-driven evolution of metastatic disease?
Soler A. (France), Cayrefourcq L. (France), Mazard T. (France), Babayan A. (Germany), Lamy P.J. (France), Pantel K. (Germany), Assou S. (France), Assenat E. (France), Alix Panabieres C. (France)

P-44
Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases - Implications as a Marker for Oligo-metastatic Disease
Wikman H. (Germany), Hasseman A. (Germany), Niebelsah C. (Germany), Mohn M. (Germany), Joosse S. (Germany), Lamszus K. (Germany), Loges S. (Germany), Westphal M. (Germany), Rietdhofer S. (Germany), Pantel K. (Germany)

P-45
Circulating tumor cell assessment in the management of advanced melanoma patients
Lucci A. (United States), Hall C. (United States), Ross M. (United States), Bowman Bauldry J. (United States), Royal R. (United States), Upshaw J. (United States)
Thursday May 3, 2018

POSTER SESSIONS

CTCS AS LIQUID BIOPSY IN CLINICAL STUDIES

P-46 Protocol optimization for mass cytometry analysis of circulating tumor cells subpopulations
Rodriguez-Martinez A. (Spain), Puche-Sanz I. (Spain), Robles-Fernandez I. (Spain), Garrido C. (Spain), Cazor Olmo J.M. (Spain), Lorente Acosta J.A. (Spain), Serrano Fernandez M.J. (Spain)

P-47 Circulating tumor cells are a strong predictor of cancer specific survival in high risk non-muscle invasive bladder cancer: final analysis of a prospective observational study
Paola G. (Italy), Gradilone A. (Italy), Chiara N. (Italy), Cristina R. (Italy), Flavia L. (Italy), Nicole C. (Italy), Ettore D.B. (Italy), Isabella S. (Italy), Enrico C. (Italy)

P-48 Ultra-high sensitive and quantitative measurement of the Prostate Specific Antigen (PSA) expressed by the Circulating Tumor Cells (CTCs) with the SIMOA immunoassay technology.
Seigneuris B. (France), Bastide M.C. (France), Rebillard X. (France), Poinas G. (France), Cayrefourcq L. (France), Alix Panabieres C. (France)

P-49 MicroRNA profile of cell lines from CTCs in colon cancer
Cayrefourcq L. (France), Alix Panabieres C. (France), Assou S. (France)

P-50 Comparative analysis of Circulating Tumour Cells detection and circulating tumor DNA in liquid biopsy for the diagnosis of early stage pancreatic adenocarcinoma
Buscail E. (France), Caumont C. (France), Alix Panabieres C. (France), Quincy P. (France), Degrandi O. (France), Marty M. (France), Merlio J.P. (France), Bedel A. (France), Moreau-Gaudry F. (France), Vendrely V. (France), Laurent C. (France), Dobernat S. (France), Chiche L. (France)

P-51 Circulating tumor cells correlate to response of immune modulating therapy in non-small cell lung cancer patients
Tammenga M. (Netherlands), de Wit S. (Netherlands), Hilterman J. (Netherlands), Schuuring E. (Netherlands), Terstappen L. (Netherlands), Groen H. (Netherlands)

P-53 Automated detection of CTCs/CTMs after size-based selection from blood of patients with melanoma
Sousa-Saline F. (France), Groult J. (France), Homsy C. (France), Tatarineva E. (France), Do-Meda L. (France), Benali-Furet N. (France), Ye F. (France), Papine A. (France), Uzan G. (France), Lebbé C. (France), Wechsler J. (France)

P-54 In vivo isolation of circulating tumor cells in different clinical settings for multiple downstream applications
Jurinik C. (Germany), Osanto S. (Netherlands), Gallierani G. (Italy), Fabbri F. (Italy)

P-55 ERA-NET-action: PROLIPSY - Early Detection of Prostate Cancer by Liquid Biopsies
Werner S. (Germany), Zabel M. (Poland), Lianidou E. (Greece), Bonci D. (Italy), Alix Panabieres C. (France), Pantel K. (Germany)

P-56 PD-L1 expression on circulating epithelial tumor cells (CETCs) is associated with immune evasion and tumor progression in breast cancer patients and differs from PD-L2 expression
Lux D. (Germany)

P-57 Circulating Tumor Cell Monitoring Did Not Predict Response To Pelvic-Directed Neoadjuvant Therapy
You Y. (United States), Hall C. (United States), Chang G.J. (United States), Bednarski B. (United States), Lee L. (United States), Cuddy A. (United States), Rodriguez-Bigas M. (United States), Messick C.A. (United States), Nickerson P. (United States), Skibber J.M. (United States), Lucci A. (United States)

15h20 - 16h05
Session 4: Poster Sessions 2 (in the Exhibition area)

IMMUNE SYSTEM AND CANCER

P-59 Zoo-1: a factor able to recruit inflammatory cells in lung cancer
Neyrinck-Leglantier D. (France), Lesage J. (France), Nawrocki-Raby B. (France), Bonnomet A. (France), Blacher S. (Belgium), Birembaut P. (France), Gilles C. (Belgium), Polette M. (France)

P-61 Oncogenic Kras control of pancreas tumor immunity
Lebleu V. (United States), Rodriges Blanka E. (United States)
CANCER CELL STEMNESS AND EPITHELIAL-MESENCHYMAL PLASTICITY

P-63 Quantifying epithelial-mesenchymal plasticity and its association with patient survival
Jolly M.K. (United States), George J. (United States), Jia D. (United States), Tripathi S.C. (United States), Xu S. (United States), Somarelli J.A. (United States), Hanash S. (United States), Levine H. (United States)

P-64 Notch pathway inhibition abolishes the resistance to TKIs conferred by EGFR gatekeeper mutations
Moraver A. (France), Bousquet E. (France)

CIRCULATING CELL-FREE MiRNA, EXOSOMES, PLATELETS

P-65 Are extracellular vesicles able to control human pluripotent stem cell fate?
Buscail E. (France), Quincy P. (France), Gounou C. (France), Raymond A.A. (France), Lamrissi-Garcia I. (France), Morvanilvier I. (France), Saitel F. (France), Moreau-Gaudry F. (France), Brisson A. (France), Bedel A. (France), Dabernat S. (France)

P-67 Evaluation of miRNA extraction technologies in a multicentric manner - relevance for a standardized clinically-relevant miRNA analysis workflow
Neumann M. (Germany), Di Pasquale F. (Germany), Shaffer J. (United States), Sprenger-Haussels M. (Germany), Schlumberger M. (Germany), Ammerlaan W. (Luxembourg), Betsou F. (Luxembourg), Af Hällström T. (Finland), Lianidou E. (Greece), Sjöback R. (Sweden), Bender S. (Germany), Schlange T. (Germany)

P-68 MicroRNA Expression profiling in Saliva from patients with Colorectal Cancer
Rapado-González O. (Spain), Mañez B. (Spain), Díaz-Peña R. (Spain), Abalol A. (Spain), Álvarez-Castro A. (Spain), Suárez-Cabrera L. (Spain), Muñoz-Moreno L. (Spain), Gil-Moreno A. (Spain), Santamaría A. (Spain), López-López R. (Spain), Suárez-Cunqueiro M.M. (Spain)

P-69 Cell Free miRNA2110 is Negatively Regulated by ZEB2
Balcık Erçin P. (Turkey), Yalım-Camci I. (Türkiye), Çetin M. (Türkiye), Odabas G. (Türkiye), Aysan A. (Türkiye), Yagci T. (Türkiye)

P-70 Evidence that circulating proteins are more promising than miRNAs for identification of patients with squamous cell carcinoma of the tongue
Boldrup L. (Sweden)

CIRCULATING TUMOR CELLS

P-73 Analysis of single circulating tumor cells (CTCs) identifies resistance mutations to ALK-inhibitor in both ALK-gene and bypass oncogenic pathways
Pailier E. (France), Faugereau V. (France), Oulhen M. (France), Quaffelec P. (France), Forcato C. (Italie), Honoré A. (France), Laporte M. (France), Lecluse Y. (France), Lacroix L. (France), Marty V. (France), Ngocamus M. (France), Nicotra C. (France), Remon J. (France), Mezquita L. (France), Planchard D. (France), Soria J.C. (France), Manaresi N. (Italie), Besse B. (France), Farace F. (France)

P-74 Persistence of circulating tumor cells in high-risk early breast cancer patients during follow-up care suggests poor prognosis - Results from the adjuvant SUCCESS A trial
de Gregorio A. (Germany), Rack B. (Germany), Fasching P.A. (Germany), Häberle L. (Germany), Friedl T.W.P. (Germany), Tesch H. (Germany), Lorenz R. (Germany), Tzschaschel M. (Germany), Fehm T. (Germany), Müller V. (Germany), Schneeweiss A. (Germany), Lichtenegger W. (Germany), Beckmann M.W. (Germany), Schlocher F. (Germany), Scholz C. (Germany), Pantel K. (Germany), Janni W. (Germany)

P-75 Circulating tumor cells in the peripheral blood and leukapheresis product of non-small cell lung cancer patients
Andree K. (Netherlands), Tamminga M. (Nederland), Mentink A. (Nederland), Hilterman J. (Nederland), Groen H. (Nederland), Terstappen L. (Nederland)

P-76 Circulating Tumour Cells as a biomarker of early/recurrent disease and therapeutic response in a preclinical model of osteosarcoma
Heymann D. (France), Chalopin A. (France), Tellez-Gabriel M. (Spain), Brown H.K. (United Kingdom), Heymann M.F. (France), Gouin F. (France)

P-77 Gene expression profile of autologous cell lines established from colon circulating tumor cells captured at sequential liquid biopsies
Cayrefourcq L. (France), Assou S. (France), Alix Panabieres C. (France)

P-78 Single-cell genetic analysis helps to validate cytopathological identification of Circulating Cancer Cells in patients with Clear Cells Renal Cell Carcinoma
Broncy L. (France), Ben Njima B. (Tunisia), Mejean A. (France), Béroud C. (France), Ben Romdhane K. (Tunisia), Irie M. (France), Hofman V. (France), Muret J. (France), Hofman P. (France), Chaabouni Bouhamed H. (Tunisia), Paterlini-Brechot P. (France)
P-79 Detection of activating and resistance mutations in single CTCs from EGFR-mutant non-small cell lung cancer patients treated by EGFR inhibitors
Oulhen M. (France), Aberlenc A. (France), Pailler E. (France), Faugeron J. (France), Mezzuita L. (France), Honoré A. (France), Remon J. (France), Lacroix L. (France), Lecluse Y. (France), Manaresi N. (Italy), Ngocamus M. (France), Nicotra C. (France), Planchard D. (France), Soria J.C. (France), Besse B. (France), Farace F. (France)

P-80 Fluorescence in situ hybridization analysis in CTCs of non-small cell lung cancer patients isolated with the PARSORTIX platform
Ntziga A. (Greece), Zavidou M. (Greece), Pollakis P. (Greece), Sardi G. (Greece), Georgoulis V. (Greece), Kotsakis A. (Greece), Lianidou E. (Greece)

P-81 Development, analytical and clinical validation of a novel multiplex RT-qPCR assay for the simultaneous quantification of four AR splice variants (AR-FL, AR-V7, AR-567es and AR-total) in circulating tumor cells of mCRPC patients
Strati A. (Greece), Zavidou M. (Greece), Angelidis I. (Greece), Bournakis E. (Greece), Georgoulis V. (Greece), Lianidou E. (Greece)

P-82 Single cell profiling of Circulating Tumor Cells: Transcriptional intra-patient heterogeneity of endocrine resistant and phenotypic markers
Reinhart F. (Germany), Franken A. (Germany), Meier-Stiegen F. (Germany), Driemel C. (Germany), Stoicklein N. (Germany), Fischer J. (Germany), Niederacher D. (Germany), Fehm T. (Germany), Neubauer H. (Germany)

P-83 Detecting Viable Circulating Tumor Cells Using Droplet Based Microfluidics
El Khoury M. (France), Eyer K. (France), Chenon G. (France), Cayrefourqc L. (France), Mazel M. (France), Bibette J. (France), Alix Panabieres C. (France), Baudry J. (France)

P-84 The rVAR2 malaria protein efficiently retrieves circulating tumor cells in a EpCAM-independent manner
Agerbæk M.Ø. (Denmark), Bang-Christensen S. (Denmark), Yang M.H. (UK), Clausen T.M. (Denmark), Ditlev S.B. (Denmark), Pereira M.A. (Denmark), Nielsen M.A. (Denmark), Choudhury S. (Denmark), Gustavsson T. (Denmark), Sorensen P. (Canada), Meyer T. (UK), Proper D. (UK), Shamsh J. (UK), Theander T.G. (Denmark), Acher A. (UK), Daugard M. (Canada), Heeschen C. (UK), Salani A. (Denmark)

P-85 Scanning Electron Microscopy of Circulating Tumor Cells and tumor-derived Extracellular Vesicles
Nanou A. (Netherlands), Flohr P. (United Kingdom), Crespo M. (United Kingdom), de Bono J. (United Kingdom), Terstappen L. (The Netherlands)

P-87 Decreasing number of circulating tumor cells in patients with urothelial carcinoma of the bladder undergoing preoperative chemotherapy and association with downstaging of the primary tumor after cystectomy: an interim analysis
Abrahamsson J. (Sweden), Sjödahl G. (Sweden), Lofgren A. (Sweden), Sörenby A. (Sweden), Ståhl O. (Sweden), Cwikiel M. (Sweden), Aaltonen K. (Sweden), Rydén L. (Sweden), Liedberg F. (Sweden)

P-88 A 3D microdevice for the in vivo trapping of cancer-associated circulating cells
Jimenez Zenteno A.K. (France), Esteve A. (France), Bou E. (France), Blatché C. (France), Vieu C. (France), Malavaud B. (France), Cerf A. (France)

P-89 The genetic heterogeneity and the molecular evolution of systemic metastatic castration resistant prostate cancer during therapy
Lousa Das Neves R.P. (Germany), Streit A. (Deutschland), Raba K. (Germany), Bongers E.K. (Deutschland), Behrens B. (Germany), Flohr P. (United Kingdom), Mateo J. (Vereinigtes Königreich), Sumanasuriya S. (Vereinigtes Königreich), Crespo M. (United Kingdom), Ebbs B. (Vereinigtes Königreich), Blatché C. (France), Vieu C. (France), Malavaud B. (France), Cerf A. (France)

P-90 Breast cancer heterogeneity: genetics, estrogen receptor, metastasis, and treatment
Babayan A. (Germany), Prieske K. (Germany), Indenbirken D. (Germany), Alawi M. (Germany), Grundhoff A. (Germany), Müller V. (Germany), Pantel K. (Germany), Josses S. (Germany)

P-91 Circulating Tumor Cells in Merkel Cell Carcinoma : Detection and MCPyV status
Boyer M. (France), Cayrefourqc L. (France), Foulongne V. (France), Dereure O. (France), Alix Panabieres C. (France)

P-92 Enrichment of paired EpCAM-high and EpCAM-low/negative CTCs within metastatic breast cancer blood samples and mutational analysis of the oncogene PIK3CA
Lampignano R. (Germany), Yang L. (Germany), Neumann M. (Germany), Franken A. (Germany), Fehm T. (Germany), Niederacher D. (Germany), Neubauer H. (Germany)

P-93 Androgen Receptor Expression in Circulating Tumor Cells of Patients with Metastatic Breast Cancer
Meier-Stiegen F. (Germany), Neubacher M. (Deutschland), Krawczyk N. (Deutschland), Neubauer H. (Germany), Janni W. (Germany), Fehm T. (Germany)

P-94 Digital droplet PCR test for detection of low abundant CTC captured on filters
Swennenhuis J.F. (Netherlands), de Wit S. (Netherlands), Terstappen L. (The Netherlands)
Thursday May 3, 2018

POSTER SESSIONS

P-95
Alpha-tubulin and detyrosinated tubulin in CTCs derived from non-small cell lung cancer (NSCLC) patients
Kallergi G. (Greece), Voumvouraki A. (Greece), Zacharopoulou N. (Greece), Stournaras C. (Greece), Martin S. (United States), Georgoulas V. (Greece)

P-96
The prognosis value of circulating tumour cells for localised prostate cancer
Lu Y.J. (United Kingdom), Xu L. (United Kingdom), Mao X. (United Kingdom), Guo T. (United Kingdom), Shaw G. (United Kingdom)

P-97
CTCs phenotypes and molecular analysis in esophageal cancer patients at the single cell level
Gallerani G. (Italy), Fici P. (Italy), Valgusti M. (Italy), de Fanti S. (Italy), Frassineti G.L. (Italy), Bonaìfe M. (Italy)

P-98
PIM-1 expression in in-vivo isolated CTCs from high-risk prostate cancer patients
Markou A. (Greece), Tzanikou E. (Greece), Chen S. (Austria), Krones T. (Austria), Swierczewska M. (Poland), Budna J. (Poland), Kuske A. (Germany), Gorges T.M. (Germany), Zabel M. (Poland), Sedlmayr P. (Austria), Panabieres C. (France), Pantel K. (Germany), Lionidou E. (Greece)

P-99
Development of a novel microfluidic CTC detection platform
Hille C. (Germany), Liu H.Y. (Germany), Horst L.J. (Germany), Babayan A. (Germany), Gorges T.M. (Germany), Haller A. (Austria), Hirtz M. (Germany), Fuchs H. (Germany), Pantel K. (Germany)

P-100
Cryopreserved CTCs Gained from DLA can be Used for In Vitro Culture
Franken A. (Germany), Driemel C. (Germany), Niederacher D. (Germany), Stoecklein N.H. (Germany), Fischer J. (Germany), Fehm T. (Germany), Neubauer H. (Germany)

P101
Gene expression analysis of circulating tumor cells in patients with head and neck squamous cell carcinoma; directed comparison of CTC-enrichment based on the EpCAM-independent PARSORTIX microfluidic device with EpCAM-based CTC isolation
Zavridou M. (Greece), Strati A. (Greece), Koutsodontis G. (Greece), Psyrri A. (Greece), Lionidou E. (Greece)

P-102
Evaluation of pre-analytical conditions for gene expression studies in CTCs
Zavridou M. (Greece), Strati A. (Greece), Lionidou E. (Greece)

P-103
Leukocyte depletion using ferrofluids to enrich circulating tumor cells from diagnostic leukapheresis
Terstappen L. (Netherlands), Mentink A. (Netherlands), Andree K. (Netherlands), Brockhuis S. (Netherlands)

P-104
Self-Seeding Microwells to Isolate and Expand Single Cells
Andree K. (Netherlands), Abali F. (Nederland), Swennenhuis J. (Nederland), Passanha F. (Nederland), Oomens L. (Netherlands), Stevens M. (Nederland), Broekmaat J. (Nederland), Terstappen L. (Nederland)

P-105
Post-Enrichment Melanoma Cell Isolation using the VyCap
Beasley A. (Australia), Oomens L. (Netherlands), Stevens M. (Netherlands), Tibbe A. (Netherlands), Broekmaat J. (Netherlands), Gray E. (Australia)

P-106
EGFR Mutational Detection in Vortex-enriched CTCs, ctDNA, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients
Sollier-Christen E. (United States), Liu H. (United States), Vuppalapaty M. (United States), Chiu M. (United States), Che J. (United States), Wilkerson C. (United States), Barzanian N. (United States), Crouse S. (United States), Carroll J. (United States), Matsumoto M. (United States), Di Carlo D. (United States), Garon E. (United States)

P-107
Detection of EGFR mutations into circulating tumor cells of patients with NSCLC by coupling cell-size based enrichment method and multiplex ddPCR
Denis J.A. (France), Benali-Furet N. (France), Guillem E. (France), Gobert A. (France), Znatiy A. (France), Uzan G. (France), Henaff D. (France), Fina F. (France), Coulet F. (France), Lacorte J.M. (France)

P-108
CTCs in Prostate Cancer: Molecular Characterization, Immunostaining and Counting by Combination of Label-free Parsortix CTC Enrichment and AdnaTest ProstateCancer Expression Profiling for PSA, PSMA, AR and AR-V7
O’Brien M. (United Kingdom), Van de Flierdt J. (Germany), Templeman A. (United Kingdom), Sprenger-Hauss M. (Germany), Mumford K. (United Kingdom), Hauch S. (Germany)

P-109
SIP-HAVA-seq as a tool to identify rare mutations and to measure DNA repair capacity in liquid biopsies
Cinquin O. (United States), Cinquin A. (United States), Taylor P. (United States)

P-110
A new workflow for monitoring and analysing circulating melanoma cells
Behrens B. (Germany), Bongers E.K. (Deutschland), Van Lierop A. (Germany), Neves R.P.L. (Germany), Guglielmi R. (Germany), Van Dalum G. (Germany), Wu J. (Germany), Wiesner U. (Germany), Knaefel W.T. (Germany), Homey B. (Germany), Stoecklein N.H. (Germany)
P-111
A workflow to evaluate PD-L1 protein expression on Circulating Tumor Cells (CTCs) from Non-Small Cell Lung Cancer (NSCLC),
Sollier-Christen E. (United States), Renier C. (United States), Wilkerson C. (United States), Hur S. (United States),
Park D.E.R. (United States), Lemaire C. (United States), Matsumoto M. (United States), Carroll J. (United States),
Crouse S. (United States), Goldman J. (United States), Garon E. (United States), Di Carlo D. (United States)

P-112
Comparison of cellsearch®, epispot and cellcollector ctc isolation techniques for early diagnostic in high-risk prostate cancer patients
Budna J. (Poland), Świerzewska M. (Poland), Cieślukowski W.A. (Poland), Mazel M. (France), Agnieszka J. (Poland), Agnieszka I. (Poland), Piotr Z. (Poland), Alix Panabieres C. (France), Andrzej A. (Poland), Maciej Z. (Poland)

P-113
Molecular characterization of negative enriched cctcs in metastatic breast and prostate cancer patients
Pereira Veiga T. (Spain), Martínez-Fernández M. (Spain), Abuin C. (Spain), López-López R. (Spain), Muinelo-Romay L. (Spain), Costa C. (Spain)

P-114
Caracterization and prognosis in triple negative breast cancer circulating tumor cells
Abreu Rodríguez M. (Spain), Cabezas P. (Spain), Abalo A. (Spain), Martinez N. (Spain), Varela V. (Spain), García P. (Spain), Sanchez L. (Spain), Lopez R. (Spain), Muinelo-Romay L. (Spain)

P-115
A 1-hour easy intracellular flow cytometry assay to detect Circulating Tumor Cells without pre-enrichment step
Lopresti A. (France), Malergue F. (France), Birnbaum D. (France), Acquaviva C. (France), Mamessier E. (France)
General Information

Venue
The Corum Conference Center
Montpellier Downtown
Esplanade Charles De Gaulle - BP 2220 - 34000 Montpellier France
www.montpellier-events.com

Registration and Accommodation:
Do not forget to register for the congress and secure your accommodation on the following link: http://ismrc2018.com/en/registration/registration

Early registration fees up to December 15th 2017
From December 16th 2017 up to April 15th 2018
After April 15th 2018
REGULAR 500,00€ 600,00€ 700,00€
GRADUATE STUDENT 280,00€ 325,00€ 375,00€
CANCER ID MEMBER 325,00€ 375,00€ 450,00€
INDUSTRY 700,00€ 900,00€ 1050,00€
GALA DINNER 85,00€ 85,00€ 85,00€

How to get there?

Getting to the Corum from the airport
- Airport shuttle – line 120 – get off at the ‘Place de l'Europe’
  (www.herault-transport.fr)
- Taxi call kiosk at airport - Tel.: +33 (0)4 67 20 65 29
- Méditerranée airport taxi group - Tel.: +33 (0)4 30 96 60 00
- Other Montpellier airport taxi group - Tel.: +33 (0)7 81 46 58 77
- Attractive discounts on a wide range of fares on all worldwide (coming soon)

Getting to the Corum from the train station
- Tram lines 2 and 4 (2 stops)
- 10 minutes’ walk

Getting to the Corum by car
- Follow signs for Montpellier - Centre Historique - Le Corum
- Covered parking is available for a charge (500 places)
- Short stay pick up/drop off points are located on the west side of Le Corum (on the bus stop level).

Contact

eventime

EVENTIME
44 bd. Périer - 13008 Marseille
Tel : +33 (0)4 91 94 54 72

REGISTRATION
Valérie ELMA
Tel : 33(0)4 67 61 66 65
Email : valerie.elma@eventime-group.com

ACCOMMODATION
Alexandra BOBAND
alexandra.boband@eventime-group.com
Tel: +33 4 91 94 30 38

SPONSORS AND PARTNERS
Djamila KERROUZI
Tel: +33 (0)4 91 94 54 72
Email: djamila.kerrouzi@eventime-group.com

SCIENTIFIC PROGRAMME, ABSTRACTS & SPEAKERS CONTACT
Christine HESSLER
Tel: +33 4 91 94 54 72
Email : christine.hessler@eventime-group.com

ETHICAL MEDTECH Evaluation - all lights are on GREEN!
The ISMRC 2018 has been evaluated and approved to be COMPLIANT.
Please find details on www.ethicalmedtech.eu
We thank the Sponsors of the ISMRC Congress 2018!
Capture and harvest of Circulating Tumor Cells from blood*

ANGLE’s Parsortix™ technology captures circulating tumor cells (CTCs) from blood*. The resulting “liquid biopsy” enables the genetic and protein analysis of the patient’s cancer which has the potential to help direct optimal therapy – so moving towards personalised cancer care.

- Capture and harvest of CTCs from a wide range of cancers including lung, breast, prostate, colo-rectal, ovarian
- Antibody independent capture – including capture of mesenchymal cells and clusters of cells
- Simple operation with minimal user intervention
- Delivers viable cells ready for molecular and functional analysis
- Workflow allows the analysis of ctDNA and CTCs from the same patient sample

*Research use only – not for use in diagnostic procedures

For more information and latest publications please visit www.angleplc.com or email parsortix@angleplc.com
BREAKING THE BARRIER OF TUMOR HETEROGENEITY
Get conclusive data by selecting, sorting and collecting pure tumor and stromal cells to clearly assign genetic variant frequency. Achieving the ultimate level of purity is a necessary step to unambiguously resolve sample heterogeneity.

NEW FEATURES
High-resolution Imaging • 96 Recoveries • High-level Automation
Benchtop Instrument • D 2.23 ft x W 2.62 ft x H 2.02 ft